BASKING RIDGE, N.J., Nov. 3, 2010 /PRNewswire/ — Regado
Biosciences, a privately held company leading the development of
antithrombotic aptamers with active control agents, announced that
Ellen McDonald, MBA, Senior Vice President and Chief Business
Officer, will be presenting at IMPACT 2010 held at the Pennsylvania
Convention Center in Philadelphia, Pennsylvania. Ms.
McDonald’s presentation will be given at 11:13 a.m. EST on
Wednesday, November 10 in the Life Science Room #106AB and will
include an overview of the Company’s pipeline with emphasis on the
lead development program, the innovative anticoagulant system,
REG1. As the oldest and most established venture conference
in the Northeast, IMPACT 2010 continues to offer topical speakers,
relevant panel sessions, cutting-edge company presentations,
unparalleled networking and visibility opportunities for both
attendees and sponsors alike.
ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private
biopharmaceutical company pioneering a new therapeutic technology
with the creation and development of proprietary controllable
aptamer drug systems. Each system comprises a
nuclease-stabilized RNA aptamer, the therapeutic effect of which
can be reversed partially or completely in real time by its
specific and complementary oligonucleotide active control agent.
This technology is being applied to injectable antithrombotics
(including anticoagulants and antiplatelet agents) in the acute and
sub-acute care cardiovascular setting, a multi-billion dollar
world-wide market in need of drugs with improved safety profiles
and a greater degree of therapeutic control. The products in
Regado’s pipeline are designed to act as optimized antithrombotics,
uniquely concomitantly minimizing the risk of ischemia and
bleeding, and, by allowing patient specific tuning of the desired
therapeutic effect, providing a safe and unique approach to
personalized medicine.
ABOUT REG1, REG2 and REG3 &
‘/>”/>
